Publication: Lysine-specific histone demethylase 1 inhibition enhances robust fetal hemoglobin induction in human β<sup>0</sup>-thalassemia/hemoglobin E erythroid cells
Issued Date
2021-11-01
Resource Type
ISSN
20388330
20388322
20388322
Other identifier(s)
2-s2.0-85126741707
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Hematology Reports. Vol.13, No.4 (2021)
Suggested Citation
Woratree Kaewsakulthong, Phitchapa Pongpaksupasin, Tiwaporn Nualkaew, Suradej Hongeng, Suthat Fucharoen, Natee Jearawiriyapaisarn, Orapan Sripichai Lysine-specific histone demethylase 1 inhibition enhances robust fetal hemoglobin induction in human β<sup>0</sup>-thalassemia/hemoglobin E erythroid cells. Hematology Reports. Vol.13, No.4 (2021). doi:10.4081/hr.2021.9215 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77671
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Lysine-specific histone demethylase 1 inhibition enhances robust fetal hemoglobin induction in human β<sup>0</sup>-thalassemia/hemoglobin E erythroid cells
Abstract
Induction of fetal hemoglobin (HbF) ameliorates the clinical severity of β-tha-lassemias. Histone methyltransferase LSD1 enzyme removes methyl groups from the activating chromatin mark histone 3 lysine 4 at silenced genes, including the γ-globin genes. LSD1 inhibitor RN-1 induces HbF levels in cultured human erythroid cells. Here, the HbF-inducing activity of RN-1 was investigated in erythroid progenitor cells derived from β0-thalassemia/ hemoglobin E (HbE) patients. The significant and reproducible increases in γ-globin transcript and HbF expression upon RN-1 treatment were demonstrated in erythroid cells with divergent HbF baseline levels, the average of HbF induction was 17.7±0.8%. RN-1 at low concentration did not affect viability and proliferation of erythroid cells, but decreases in cell number were observed in cells treated with RN-1 at high concen-tration. Delayed terminal erythroid differentiation was revealed in β0-thalassemia/HbE erythroid cells treated with RN-1 as similar to other compounds that target LSD1 activ-ity. Downregulation of repressors of γ-globin expression; NCOR1 and SOX6, was observed in RN-1 treatment. These findings provide proof of the concept that LSD1 epigenetic enzyme is a potential therapeutic target for β0-thalassemia/HbE patients.